286 related articles for article (PubMed ID: 34971845)
21. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
22. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
Szebeni J; Storm G; Ljubimova JY; Castells M; Phillips EJ; Turjeman K; Barenholz Y; Crommelin DJA; Dobrovolskaia MA
Nat Nanotechnol; 2022 Apr; 17(4):337-346. PubMed ID: 35393599
[TBL] [Abstract][Full Text] [Related]
23. Are the Allergic Reactions of COVID-19 Vaccines Caused by mRNA Constructs or Nanocarriers? Immunological Insights.
Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
Interdiscip Sci; 2021 Jun; 13(2):344-347. PubMed ID: 34021862
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
25. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
[No Abstract] [Full Text] [Related]
26. Incidence of immediate allergic reactions to mRNA COVID-19 vaccines in adults with drug allergies and other allergic disorders.
Marković I; Božan M; Perković T; Paušek K; Nedeljković V; Perković M; Kelava T; Artuković M; Stipić Marković A
Medicine (Baltimore); 2022 Jul; 101(30):e29571. PubMed ID: 35905225
[TBL] [Abstract][Full Text] [Related]
27. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
;
MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
[TBL] [Abstract][Full Text] [Related]
28. Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine.
Maron JS; Conroy M; Naranbai V; Samarakoon U; Motazedi T; Farmer JR; Freeman E; Banerji A; Bartsch YC; Gregory DJ; Poznansky MC; Alter G; Blumenthal KG
J Infect Dis; 2022 Sep; 226(7):1231-1236. PubMed ID: 35325158
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
30. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.
Shimabukuro T
Am J Transplant; 2021 Mar; 21(3):1326-1331. PubMed ID: 33641268
[No Abstract] [Full Text] [Related]
31. Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan.
Akaishi T; Onodera T; Takahashi T; Harigae H; Ishii T
Sci Rep; 2022 Sep; 12(1):15510. PubMed ID: 36109582
[TBL] [Abstract][Full Text] [Related]
32. Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan.
Akaishi T; Onodera T; Takahashi T; Harigae H; Ishii T
Tohoku J Exp Med; 2023 Mar; 259(4):263-271. PubMed ID: 36642506
[TBL] [Abstract][Full Text] [Related]
33. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
Desai AP; Desai AP; Loomis GJ
Vaccine; 2021 Jul; 39(32):4407-4409. PubMed ID: 34215453
[TBL] [Abstract][Full Text] [Related]
34. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
35. Anaphylaxis is a rare reaction in COVID-19 vaccination.
Bellomo RG; Gallenga CE; Caraffa A; Tetè G; Ronconi G; Conti P
J Biol Regul Homeost Agents; 2021; 35(3):839-842. PubMed ID: 34105336
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 Vaccine Hesitancy and Early Adverse Events Reported in a Cohort of 7,881 Italian Physicians.
Monami M; Gori D; Guaraldi F; Montalti M; Nreu B; Burioni R; Mannucci E
Ann Ig; 2022; 34(4):344-357. PubMed ID: 34821928
[TBL] [Abstract][Full Text] [Related]
37. Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis.
Stone CA; Garvey LH; Nasser S; Lever C; Triggiani M; Parente R; Phillips EJ
J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2008-2022. PubMed ID: 37182566
[TBL] [Abstract][Full Text] [Related]
38. Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics.
Otani IM; Tsao LR; Tang M
Ann Allergy Asthma Immunol; 2022 Jul; 129(1):88-94.e1. PubMed ID: 35288274
[TBL] [Abstract][Full Text] [Related]
39. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022.
Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV
MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
